Haemonetics Corporation (HAE) Return on equity 2017–2026
Haemonetics Corporation (HAE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
12.2%FY2026 · since FY2017: -3.6% → 12.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 12.2% | -8.2 pp |
| FY2025 | 20.4% | +8.2 pp |
| FY2024 | 12.2% | -1.9 pp |
| FY2023 | 14.1% | +8.3 pp |
| FY2022 | 5.8% | -5.1 pp |
| FY2021 | 10.9% | -2.2 pp |
| FY2020 | 13.0% | +4.8 pp |
| FY2019 | 8.2% | +2.2 pp |
| FY2018 | 6.1% | +9.6 pp |
| FY2017 | -3.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice